Opinion|Videos|January 2, 2025
Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases
Panelists discuss how they approach the treatment of HER2-positive advanced breast cancer with brain metastases, outlining the criteria for therapy selection, the role of patient-specific factors in shaping treatment strategies, and situations where they might adjust their approach.
Advertisement
Video content above is prompted by the following:
- How do you generally approach the treatment of patients with HER2-positive advanced breast cancer and brain metastases?
- What criteria guide your selection among available therapies, and how do specific patient factors influence your strategy?
- Are there factors that may lead you to deviate from your approach?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93
5